Anxiety sensitivity and medication nonadherence in patients with uncontrolled hypertension by Alcantara, Carmela et al.
Anxiety Sensitivity and Medication Nonadherence in Patients
with Uncontrolled Hypertension
Carmela Alcántara, PhD, Donald Edmondson, PhD, MPH, Nathalie Moise, MD, Desiree
Oyola, B.A., David Hiti, MA, and Ian M. Kronish, MD, MPH
Center for Behavioral Cardiovascular Health, Department of Medicine, Columbia University
Medical Center, New York, New York 10032
Abstract
Objective—Anxiety sensitivity—fear of the negative social, physical, or cognitive consequences
of anxiety related sensations — has been linked to cardiovascular disease and adverse
cardiovascular health behaviors. Medication nonadherence may account for this association. We
examined whether anxiety sensitivity was independently associated with objectively measured
medication nonadherence in a multi-ethnic primary care sample.
Methods—Eighty-eight patients with uncontrolled hypertension completed the Anxiety
Sensitivity Index and had their adherence to blood pressure (BP) medications measured during the
interval between two primary care visits using an electronic pillbox (MedSignals®). Multivariable
Poisson regressions were conducted to determine the relative risks of medication nonadherence
associated with anxiety sensitivity after adjustment for age, gender, Hispanic/Latino ethnicity,
education, total number of prescribed medications, and depressive and posttraumatic stress
disorder (PTSD) symptoms.
Results—Nearly twice as many patients with high anxiety sensitivity were nonadherent to BP
medications compared to patients with low anxiety sensitivity (65.0% vs. 36.8%; p=0.03). Patients
with high anxiety sensitivity had higher relative risks of medication nonadherence than their low
anxiety sensitivity counterparts (adjusted relative risk [RR]=1.76; 95% CI: 1.03–3.03).
Conclusions—In this first study of the association between anxiety sensitivity and medication
adherence, we found that high anxiety sensitivity was strongly associated with BP medication
nonadherence, even after adjustment for known confounders. Our results suggest that teaching
patients who have uncontrolled hypertension adaptive strategies to manage their anxiety
sensitivity may help improve their medication adherence, and thereby lower their cardiovascular
risk.
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Anxiety sensitivity— fear of the negative social, physical, or cognitive consequences of
anxiety-related sensations1–3—has been linked to cardiovascular disease4,5 and adverse
cardiovascular health behaviors.5–11 Anxiety sensitivity is considered a multi-dimensional
and trait-like cognitive vulnerability that exacerbates antecedent levels of anxiety. It is
composed of three lower-order and interrelated factors pertaining to fear of anxiety: social
concerns (e.g., belief that observable anxiety symptoms will lead to social rejection),
physical concerns (e.g., belief that palpitations result in cardiac arrest/heart attack), and
cognitive concerns (e.g., belief that concentration difficulties result in mental
incapacitation).12,13 For example, individuals with high anxiety sensitivity are more likely to
make catastrophic interpretations of arousal-related sensations of anxiety and in turn
experience increased anxiety, which creates a positive feedback loop and escalating cycle.3
This tendency to fear and catastrophize anxiety-related or arousal-related sensations is
thought to lead to avoidance behaviors that limit or remove altogether exposures to anxiety-
provoking triggers, situations, and contexts.2
While anxiety sensitivity has been linked to certain cardiovascular health risk behaviors
including smoking, drinking alcohol, using ilicit drugs, and being less likely to exercise,7–9
to our knowledge, no prior studies have examined the association between anxiety
sensitivity and adherence to cardiovascular medications. Medication nonadherence is an
established risk factor for cardiovascular disease,14 and may account for the association
between anxiety sensitivity with cardiovascular disease. Anxiety sensitivity may influence
medication adherence as it is possible that patients with high anxiety sensitivity experience
increased anxiety in the context of perceived medication side-effects or as a response to their
hypertension symptoms that mimic anxiety-related sensations; this may lead to avoidance of
medications and worse overall medication adherence. Indeed, common side-effects to BP
medications and common symptoms of hypertension include dizziness, headaches, and
palpitations,15,16 which are also common symptoms of anxiety or arousal.17 We examined
whether anxiety sensitivity was independently associated with objectively measured
medication nonadherence in a multi-ethnic sample of primary care patients with
uncontrolled hypertension. We also explored whether or not specific subscales of anxiety
sensitivity predicted medication nonadherence. We were particularly interested in the
association of anxiety sensitivity to medication nonadherence independent of depressive
symptoms and posttraumatic stress disorder symptoms, two well-established and consistent
predictors of medication nonadherence.18–20 We also tested whether anxiety sensitivity was
associated with increased self-reported side-effects to BP medications. We hypothesized that
individuals with high anxiety sensitivity would be more likely to exhibit poor medication
adherence and to report medication side-effects.
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We enrolled a convenience sample of patients with uncontrolled hypertension from a
hospital-based primary care clinic in New York City. Patients were eligible if they had
elevated blood pressure [BP] on two consecutive clinic visits prior to enrollment (BP ≥
140/90 mm Hg or ≥ 130/80 if they had diabetes mellitus or chronic kidney disease) and if
they were prescribed at least one BP medication. Patients were ineligible if they were unable
to self-manage their BP medications due to dementia, psychosis, active substance abuse, or
if they resided in an institutional setting.
Medication adherence was assessed during the interval between two subsequent clinic visits
using an electronic pillbox with four compartments (MedSignals; MedSignals Corporation).
Each BP medication was stored in a separate compartment, and the pillbox recorded the date
and time that each compartment was opened. Adherence to each medication was calculated
as the percent of days the correct number of doses were taken as prescribed; adherence to
the overall BP medication regimen was calculated as the mean adherence to all monitored
medications. Anxiety sensitivity was assessed using the Anxiety Sensitivity Index (ASI)
administered in either English or Spanish after completing adherence monitoring.21 The
Anxiety Sensitivity Index has strong psychometric properties and has been validated in
multiple Spanish-speaking samples.22 The internal consistency of this scale was excellent in
our sample (Cronbach’s ∞ =0.91). Total ASI scores were dichotomized into high (ASI ≥
36) and low (ASI <36) anxiety sensitivity categories based on established cut-offs that
correspond to clinically significant anxiety levels.23 In an exploratory analysis, we also
calculated total scores for each of the three purported ASI subscales: Physical Concerns,
Cognitive Concerns, and Social Concerns.24 Patients’ age, gender, ethnicity, and years of
education were ascertained by self-report. Depressive symptoms at baseline were measured
using the Patient Health Questionnaire (PHQ-8).25 Posttraumatic stress disorder (PTSD)
symptoms were measured using the Primary Care PTSD screening questionnaire.26 Number
of total prescribed medications was extracted from the electronic medical record. Patients
were also asked whether (yes/no) they experienced side-effects from their BP medications.
The Institutional Review Board of Columbia University Medical Center approved this study.
Patients were categorized as nonadherent if their adherence to their BP regimen was less
than 80%.27 We conducted Chi-square tests, independent samples t-tests, and independent
samples Mann Whitney U tests (when variables were not normally distributed) to examine
the distribution of demographic and behavioral variables by anxiety sensitivity status. We
used logistic regression to determine whether anxiety sensitivity was associated with
objectively measured medication nonadherence, independent of age, gender, ethnicity,
education, number of prescribed medications, depressive symptoms, and PTSD symptoms.
Model 1 estimated the unadjusted association of anxiety sensitivity with medication
nonadherence. Model 2 included adjustment for demographics (age, gender, Hispanic/Latino
ethnicity, education) and total number of prescribed medications. Model 3 included a final
adjustment for depressive symptoms and PTSD symptoms at baseline because prior research
has shown that depression and PTSD are associated with medication nonadherence and thus
potentially important confounders.19,20 Separately, we also examined whether each of the
ASI subscales was associated with medication nonadherence in unadjusted models and
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whether ASI was associated with medication nonadherence when adding a measure of state
anxiety (PROMIS – anxiety)28 to the fully adjusted model. As there was a high
nonadherence rate, we used a Modified Poisson regression with a robust error variance29 to
determine the adjusted relative risks.
Results
Between October 2011 and November 2013, 113 patients enrolled in the study; 88 had
usable pillbox data and complete covariate information. Overall, patients had a mean age of
64.65 (SD = 8.06) years, 68 were women (77.3%), 72 were Hispanic/Latino (81.8%), and
patients had a mean of 8.52 (SD = 4.42) years of education. The mean ASI score was 23.55
(SD = 14.93), and 22.7% had high anxiety sensitivity. Patients with high compared to low
anxiety sensitivity did not significantly differ from each other on age, gender, ethnicity,
years of education, PTSD symptoms, depressive symptoms, or total number of prescribed
medications (Table 1). Patients took 10.85 (SD = 4.12) prescribed medications on average.
Adherence was monitored for a mean of 62.41 days (SD = 44.53; range: 359) and 43.2% of
patients were nonadherent (<80% of days). Patients with high anxiety sensitivity were also
more likely than patients with low anxiety sensitivity to report having side effects from their
BP medications (50.0% vs. 23.1%, p = .01) (Table 1).
Nearly twice as many patients with high anxiety sensitivity were nonadherent to BP
medications compared to patients with low anxiety sensitivity (65.0% vs. 36.8%; p = 0.03).
Patients with high anxiety sensitivity had higher relative risks of medication nonadherence
than their low anxiety sensitivity counterparts in unadjusted models (RR =1.77; 95% CI:
1.13–2.77), and after adjustment for age, gender, ethnicity, and number of prescribed
medications (RR = 1.86; 95% CI: 1.15–2.99), and further adjustment for depressive and
PTSD symptoms at baseline (RR = 1.76; 95% CI: 1.03–3.03). Although there was a trend
for number of PTSD symptoms (p =.07), high anxiety sensitivity was the only factor
significantly associated (p =.04) with medication nonadherence in our models. Our
exploratory analyses indicate that the Cognitive Concerns (RR=1.06; 95%CI: 1.01–1.11)
and the Social Concerns (RR=1.08; 95%CI: 1.02–1.15) anxiety sensitivity subscales were
particularly predictive of medication nonadherence. Although the Physical Concerns
subscale was not statistically associated with medication nonadherence, the relative risk was
in the expected direction (RR=1.02; 95%CI: 0.99–1.04).
We conducted a sensitivity analysis wherein we treated anxiety sensitivity as a continuous
variable, and found that anxiety sensitivity was linearly associated with risk of medication
nonadherence (adjusted RR =1.02; 95%CI: 1.00–1.04). We also conducted an additional
sensitivity analysis where we included state anxiety, as measured by the PROMIS anxiety
scale,28 as an additional covariate in our final model. Our results did not change appreciably,
although we lost some statistical power by including another covariate in the model. High
anxiety sensitivity (RR=1.72, 95%CI: 0.98–3.00) was marginally associated with
medication nonadherence, whereas state anxiety (RR=1.00, 95%CI: 0.94–1.07) was not.
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In this first study on the association of anxiety sensitivity with medication adherence, we
found that high anxiety sensitivity was associated with nearly double the risk of
nonadherence to BP medications, even after adjustment for potential confounders. In this
sample, the relative risk of medication nonadherence associated with high anxiety sensitivity
(RR=1.76) was of the same magnitude as that reported for depression in a meta-analysis of
the association between depression and medication nonadherence (RR=1.74).19 None of the
other demographic and behavioral factors were significantly associated with medication
nonadherence in this sample. We also found that cognitive concerns and social concerns
about anxiety-related sensations were particularly predictive of medication non-adherence.
Patients with high anxiety sensitivity were also more likely to report experiencing side-
effects from their BP medications.
These results suggest that anxiety sensitivity may be an important yet vastly understudied
psychological determinant of BP medication nonadherence in primary care patients with
uncontrolled hypertension who are at increased risk for cardiovascular disease. Patients with
high anxiety sensitivity might be more likely to misattribute their regular bodily sensations
to their hypertension medications and to avoid their BP medications altogether.
Alternatively, patients with high anxiety sensitivity might be more hypervigilent of their
perceived BP medication side effects (e.g., dizziness) that mimic anxiety symptoms and
trigger social and cognitive concerns regarding anxiety or arousal, which in turn leads to
worse medication adherence. Indeed, in our sample, patients with high anxiety sensitivity
were more likely than patients with low anxiety sensitivity to report having side effects from
their BP medications, although our data did not allow us to assess for specific types of side
effects. Relatedly, patients with uncontrolled hypertension and with high anxiety sensitivity
might also consciously or unconsciously avoid all reminders of their illness, such as their BP
medications, which might remind them of their hypertension status and threatening
physiology.
While this is the first empirical report to examine the association of anxiety sensitivity with
objectively measured medication adherence, our study is not without its limitations. First,
this is a cross-sectional study, and thus we are unable to make causal inferences or rule out
reserve causality. Future research should use longitudinal designs to examine the long-term
effects of anxiety sensitivity in primary care samples, using more contemporary measures of
the construct (ASI-3)12 that can reliably assess the three purported dimensions of anxiety
sensitivity, on medication nonadherence and other health behaviors such as smoking and
alcohol use, and explore whether treatment of anxiety sensitivity improves medication
adherence. Future research should also use larger samples to more comprehensively
examine whether anxiety sensitivity and state anxiety are differentially associated with
medication nonadherence. Second, this study was drawn from a small convenience sample
of patients from a single primary care clinic, and hence its findings may not be generalizable
to other populations. Relatedly, given the small sample size, we were not statistically
powered to explore whether gender moderates the association of anxiety sensitivity to
medication non-adherence, though prior work has shown that depression and anxiety might
have differential implications for medication adherence among men and women.30 Third,
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we did not conduct comprehensive assessments of psychiatric disorders such as those
generated from clinical interviews such as the CAPS for PTSD or the SCID, and thus cannot
rule out whether the association of anxiety sensitivity with medication nonadherence is due
to confounding from a psychiatric disorder. However, in models that adjusted for depression
and PTSD symptoms, and in sensitivity analyses that further adjusted for state anxiety, we
continued to see a robust association between anxiety sensitivity and medication
nonadherence. This suggests that anxiety sensitivity is a psychological vulnerability that is
independent of other psychological markers of medication nonadherence19,20 and thus might
be particularly relevant for medication adherence in patients at risk of cardiovascular
disease.
In conclusion, our results show that patients with high anxiety sensitivity are more likely to
exhibit medication nonadherence than their low-anxiety sensitivity counterparts. Our results
suggest that teaching patients adaptive strategies to manage their anxiety sensitivity,
particularly focused on managing their cognitive and social concerns regarding anxiety- or
arousal-related sensations, might help them improve their medication adherence, and
thereby lower their cardiovascular risk.
Acknowledgments
This work was supported by funds from the National Heart Lung, and Blood Institute at the National Institutes of
Health (R01 HL115941-01S1 to CA, R01 HL117832 to D.E., K23 HL-098359 to I.M.K.), the American Heart
Association (SDG 10SDG2600321 to I.M.K.) and the Health Resources and Services Administration (T32HP10260
to N.M.).
References
1. Reiss S, Peterson RA, Gursky DM, McNally RJ. Anxiety sensitivity, anxiety frequency and the
prediction of fearfulness. Behavior Research and Therapy. 1986; 24:1–8.
2. Olatunji BO, Wolitzky-Taylor KB. Anxiety sensitivity and the anxiety disorders: a metaanalytic
review and synthesis. Psychol Bull. 2009 Nov; 135(6):974–999. [PubMed: 19883144]
3. Reiss, S.; McNally, RJ. Expectancy model of fear. In: Reiss, S.; Bootzin, RR., editors. Theoretical
issues in behavior therapy. San Diego, CA: Academic; 1985. p. 107-121.
4. Seldenrijk A, van Hout HP, van Marwijk HW, et al. Sensitivity to depression or anxiety and
subclinical cardiovascular disease. J Affect Disord. 2012 Aug 6.
5. Frasure-Smith N, Lesperance F, Talajic M, et al. Anxiety sensitivity moderates prognostic
importance of rhythm-control versus rate-control strategies in patients with atrial fibrillation and
congestive heart failure: insights from the Atrial Fibrillation and Congestive Heart Failure Trial.
Circ Heart Fail. 2012 May 1; 5(3):322–330. [PubMed: 22441774]
6. Smits JA, Tart CD, Presnell K, Rosenfield D, Otto MW. Identifying potential barriers to physical
activity adherence: anxiety sensitivity and body mass as predictors of fear during exercise.
Cognitive behaviour therapy. 2010 Mar; 39(1):28–36. [PubMed: 19675961]
7. Zvolensky MJ, Buckner JD, Norton PJ, Smits JAJ. Anxiety, substance use, and their cooccurrence:
Advances in clinical science. Journal of Cognitive Psychotherapy. 2011; 25(1):3–6. [PubMed:
21857769]
8. Wong M, Krajisnik A, Truong L, et al. Anxiety sensitivity as a predictor of acute subjective effects
of smoking. Nicotine & tobacco research : official journal of the Society for Research on Nicotine
and Tobacco. 2013 Jun; 15(6):1084–1090. [PubMed: 23144083]
9. Gonzalez A, Zvolensky MJ, Vujanovic AA, Leyro TM, Marshall EC. An evaluation of anxiety
sensitivity, emotional dysregulation, and negative affectivity among daily cigarette smokers:
Alcántara et al. Page 6













relation to smoking motives and barriers to quitting. Journal of psychiatric research. 2008 Dec;
43(2):138–147. [PubMed: 18417153]
10. Smits JA, Tart CD, Rosenfield D, Zvolensky MJ. The interplay between physical activity and
anxiety sensitivity in fearful responding to carbon dioxide challenge. Psychosomatic medicine.
2011 Jul-Aug;73(6):498–503. [PubMed: 21700713]
11. Ong L, Cribbie R, Harris L, et al. Psychological correlates of quality of life in atrial fibrillation.
Qual Life Res. 2006 Oct; 15(8):1323–1333. [PubMed: 16826433]
12. Taylor S, Zvolensky MJ, Cox BJ, et al. Robust dimensions of anxiety sensitivity: development and
initial validation of the Anxiety Sensitivity Index-3. Psychological assessment. 2007 Jun; 19(2):
176–188. [PubMed: 17563199]
13. Taylor, S. Anxiety sensitivity: Theory, research, and treatment of the fear of anxiety. Routledge:
1999.
14. Kronish IM, Ye S. Adherence to cardiovascular medications: lessons learned and future directions.
Prog Cardiovasc Dis. 2013 May-Jun;55(6):590–600. [PubMed: 23621969]
15. Marshall IJ, Wolfe CD, McKevitt C. Lay perspectives on hypertension and drug adherence:
systematic review of qualitative research. BMJ (Clinical research ed.). 2012; 345:e3953.
16. Benson J, Britten N. What effects do patients feel from their antihypertensive tablets and how do
they react to them? Qualitative analysis of interviews with patients. Family practice. 2006 Feb;
23(1):80–87. [PubMed: 16107491]
17. Lavoie, K. Anxiety. In: Gellman, MD.; Turner, JR., editors. Encyclopedia of behavioral medicine.
New York: Springer; 2013. p. 106-108.
18. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment
outcomes: a meta-analysis. Medical care. 2002 Sep; 40(9):794–811. [PubMed: 12218770]
19. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with
medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence.
Archives of internal medicine. 2000 Jul 24; 160(14):2101–2107. [PubMed: 10904452]
20. Kronish IM, Lin JJ, Cohen BE, Voils CI, Edmondson D. Posttraumatic Stress Disorder and
Medication Nonadherence in Patients With Uncontrolled Hypertension. JAMA Intern Med. 2013
Dec 2.
21. Peterson, RA.; Reiss, S. Anxiety Sensitivity Index. 2ed.. Worthington, OH: International
Diagnostic Systems; 1992.
22. Cintrón JA, Carter MM, Suchday S, Sbrocco T, Gray J. Factor structure and construct validity of
the Anxiety Sensitivity Index among island Puerto Ricans. Journal of anxiety disorders. 2005;
19:51–68. [PubMed: 15488367]
23. Reiss, S.; Peterson, RA.; Taylor, S.; Schmidt, N.; Weems, CF. Anxiety Sensitivity Index
consolidated user manual: ASI, ASI-3, and CASI. Worthington, OH: IDS Publishing; 2008.
24. Zinbarg RE. Hierarchical structure and general factor saturation of the Anxiety Sensitivity Index:
Evidence and implications. Psychological assessment. 1997; 9(3):277–284.
25. Kroenke K, Strine TW, Spitzer RL, Williams JB, Berry JT, Mokdad AH. The PHQ-8 as a measure
of current depression in the general population. J Affect Disord. 2009 Apr; 114(1–3):163–173.
[PubMed: 18752852]
26. Freedy JR, Magruder KM, Zoller JS, Hueston WJ, Carek PJ, Brock CD. Traumatic events and
mental health in civilian primary care: implications for training and practice. Family medicine.
2010 Mar; 42(3):185–192. [PubMed: 20204894]
27. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular
outcomes. Circulation. 2009 Jun 16; 119(23):3028–3035. [PubMed: 19528344]
28. Pilkonis PA, Choi SW, Reise SP, Stover AM, Riley WT, Cella D. Item banks for measuring
emotional distress from the Patient-Reported Outcomes Measurement Information System
(PROMIS(R)): depression, anxiety, and anger. Assessment. 2011 Sep; 18(3):263–283. [PubMed:
21697139]
29. Zou G. A Modified Poisson Regression Approach to Prospective Studies with Binary Data.
American Journal of Epidemiology. 2004 Apr 1; 159(7):702–706. 2004. [PubMed: 15033648]
30. Gentil L, Vasiliadis HM, Preville M, Bosse C, Berbiche D. Association between depressive and
anxiety disorders and adherence to antihypertensive medication in community-living elderly
Alcántara et al. Page 7













adults. Journal of the American Geriatrics Society. 2012 Dec; 60(12):2297–2301. [PubMed:
23110563]
Alcántara et al. Page 8














• We examined the association of anxiety sensitivity with medication
nonadherence
• Medication nonadherence was measured objectively in patients with
hypertension
• High anxiety sensitivity was strongly associated with BP medication
nonadherence
• Those with high vs low anxiety sensitivity had a 76% increased risk of
nonadherence
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